Bernstein D, et al. - In this open-label, single-arm, phase 3a study, researchers assessed mepolizumab for its usability as a liquid drug product self-administered via a single-use prefilled autoinjector (AI) by patients with severe eosinophilic asthma (SEA), or their caregivers, in-clinic and at home. Participants were patients (aged ≥ 12 years) with SEA who were either taking mepolizumab (100 mg subcutaneously [SC]) every 4 weeks (Q4W) for ≥ 12 weeks prior to screening or not taking mepolizumab but satisfied criteria suggestive of SEA. For 12 weeks, mepolizumab (100 mg SC) was self-administered via an AI Q4W by patients/caregivers. Findings revealed that, both in-clinic and at home, mepolizumab was successfully self-administered via the AI by patients/caregivers—with no new safety concerns.